{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-26-000055","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2026-10-23T10:07:04+00:00","discovered_at":"2026-10-23T10:10:00.391303+00:00","generated_at":"2026-10-23T10:10:04.181144+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zymeworks licenses DLL3 T-cell engager ZW209 to Roche for $55M upfront, up to $758M in milestones","bullets":["Roche pays $55M upfront after HSR clearance, plus a $40M milestone on the first ZW209 Phase 1b trial; up to $718M in development, commercial and sales milestones.","Zymeworks also gets tiered high-single-digit to mid-teen royalties on global net sales, payable until the later of 10 years post-launch or patent expiry (patents into the 2040s).","Zymeworks runs the Phase 1a monotherapy trial at Roche's expense; Roche funds it and takes over all later global development, manufacturing and commercialization.","Exclusive worldwide license covers ZW209 and other DLL3 trispecific T-cell engagers; Zymeworks is barred from DLL3 T-cell engager work for up to 5 years or first Phase 3 start.","FDA IND clearance for ZW209 received; deal still subject to HSR waiting period; investor call October 27 at 8:30 am ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-26-000055","json":"https://secwatch.observer/filing/0001937653-26-000055.json","markdown":"https://secwatch.observer/filing/0001937653-26-000055.md","text":"https://secwatch.observer/filing/0001937653-26-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765326000055/0001937653-26-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765326000055/zyme-20261022.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-23T10:10:04.181144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}